HPV Vaccine Development Solutions

Human papillomavirus (HPV) is one of the most prevalent sexually transmitted pathogens worldwide and is strongly associated with cervical cancer, anal cancer, vulvar cancer, vaginal cancer, penile cancer, and oropharyngeal cancer. Persistent infection with high-risk HPV genotypes, particularly HPV16 and HPV18, accounts for the majority of HPV-related malignancies.

The successful introduction of prophylactic HPV vaccines has significantly reduced HPV infection rates and disease burden. As next-generation multivalent HPV vaccines continue to advance, there is an increasing demand for reliable reagents and analytical tools to support vaccine development, immunogenicity evaluation, potency testing, and quality control.

Understanding HPV Immune Responses and Immune Evasion

Most HPV infections are cleared naturally, with over 90% of cases resolving within a few years. However, some infections persist and can progress to precancerous or malignant lesions. HPV employs multiple immune evasion strategies to establish long-term infections, such as suppressing interferon responses and evading antigen presentation.

For vaccine development and immunogenicity evaluation, several viral components are particularly important:

L1 Major Capsid Protein: Main antigen in prophylactic vaccines; forms virus-like particles (VLPs) that induce neutralizing IgG antibodies to block viral entry.

L2 Minor Capsid Protein: Involved in immune evasion and viral infectivity; a potential target for broadly protective vaccines.

E6 and E7 Oncoproteins: Disrupt cell cycle and suppress interferon-mediated immunity; primary targets for therapeutic vaccine strategies.

Figure 1. HPV structure and major antigenic components involved in vaccine-induced immune responses

Licensed Prophylactic HPV Vaccines and Evolving Vaccine Landscape

The success of prophylactic HPV vaccination represents one of the most important achievements in cancer prevention. Since the introduction of the first HPV vaccine, multiple generations of vaccines have been developed to expand genotype coverage and improve population protection. Current licensed vaccines are all based on L1 virus-like particle (VLP) technology, which has demonstrated excellent safety profiles and long-lasting immunogenicity.

The evolution from bivalent and quadrivalent vaccines to nonavalent formulations has increased protection against oncogenic HPV types responsible for the majority of cervical cancers worldwide. As vaccine valency continues to expand, the complexity of immunogenicity assessment, potency evaluation, and quality control also increases, creating a growing need for standardized analytical reagents and functional assays.

These vaccines established VLP-based immunization as the gold standard and have created strong demand for reliable immunogenicity evaluation and analytical tools.

Key Analytical Reagents Supporting HPV Vaccine Development

To support vaccine development and evaluation, several categories of analytical reagents are essential:

Neutralizing Monoclonal Antibodies

These antibodies are critical for:

• Potency assay development
• Epitope mapping
• Assay qualification and standardization
• Reference standards
• Competitive binding studies

Recombinant HPV Antigens and VLP Reagents

Virus-like particles (VLPs) structurally resemble native virions but lack viral DNA, inducing robust humoral immune responses while maintaining an excellent safety profile. Recombinant antigens and VLP-based reagents are essential for:

• Antibody detection and ELISA development
• Immunogenicity studies
• Vaccine characterization
• Assay calibration and quality control

These reagents collectively support both monovalent and multivalent vaccine programs, covering multiple high-risk and low-risk HPV genotypes.

HPV L1 Antibodies for Neutralization and Vaccine Development

Creative Diagnostics has launched the most complete HPV L1 antibody products, covering HPV 6/11/16/18/31/33/45/52/58, including polyclonal, monoclonal antibody and monoclonal antibody screening set, mainly used for ELISA, Western Blot, neutralization and in vitro vaccine in vitro efficacy testing. View More

Neutralizing monoclonal antibody sets:

*The antibodies are provided as screening sets (6 different clones per set), each clone is also available separately.

HPV broad-spectrum antibodies

Polyclonal antibodies For WB

Recombinant HPV L1 VLP

Creative Diagnostics has established a global-leading virus-like particles (VLPs) manufacture platform using E. coli cell system. With years of exploration, our scientists have successfully obtained various highly purified HPV VLPs. Our products have significantly contributed to the HPV vaccine related research. View More

HPV Pseudovirus

The CD Pseudotyped GFP HPV production is based on the transfection of a 293 cell line, 293FT, engineered to express high levels of SV40 large T antigen. The cells are co-transfected with codon-modified papillomavirus capsid genes, L1 and L2, together with a pseudogenome plasmid containing the SV40 origin of replication. Pseudovirus (PsV) encapsidating a GFP reporter plasmid can be used to develop a high-throughput in vitro neutralization assay in a 96-well plate format. View More

Resources

HPV mAb Set Specificity